AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01882127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
Study NCT01882127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA\&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
Study NCT04453475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
Study NCT04453475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training session adressing information and health literacy
Description: The training sessions are provided online and as alternative to face-to-face treatments which cannot be provided as before due to the safety regulations relating to Covid-19
Study NCT01554696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT03568422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402257
Description: Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16
Study NCT03568422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV days 1, 8 \& 15 every 28 days
Study NCT04146103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novex
Description: Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
Study NCT01527552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
Study NCT00571259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin 1000U/mL
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study NCT00571259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Sodium Citrate with Gentamicin 320 mcg/mL
Description: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
Study NCT03153163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
Study NCT01554696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01554696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: oral
Study NCT02915549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Feeding without MEF
Description: This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
Study NCT02915549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Feeding with MEF
Description: This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handgrip strength
Description: First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door handle device
Description: To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tap device
Description: To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door pull handle
Description: To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear Switch device
Description: To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
Study NCT04174729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door Key device
Description: To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
Study NCT01554696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: oral
Study NCT00887900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Description: Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
Study NCT00887900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrated keratoplasty
Description: Regular corneal transplant using the penetrated keratoplasty technique
Study NCT02707614 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic vs open prostastectomy
Description: robotic minimal invasive surgery
Study NCT03256552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 28.8 micrograms
Description: Glycopyrronium MDI 28.8 micrograms
Study NCT03256552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 14.4 micrograms
Description: Glycopyrronium MDI 14.4 micrograms
Study NCT03256552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium MDI 7.2 micrograms
Description: Glycopyrronium MDI 7.2 micrograms
Study NCT03256552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo Inhalation Aerosol
Study NCT03272594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Description: Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
Study NCT03272594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% oral sucrose
Description: Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
Study NCT00003217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT03056456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT00003217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT01670357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034 3%
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study NCT01670357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034 5%
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study NCT01670357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-6034 Placebo
Description: Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
Study NCT00973791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
Study NCT00973791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
Study NCT03277846 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
Study NCT03277846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexalin Based Trans-Cranial Electrical Stimulation
Description: The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
Study NCT03638817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is \< 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count
Study NCT03056456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog)
Description: Administered SC
Study NCT02647632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Study NCT02647632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT01888497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 250 mg, oral, prior to bedtime on the night before performance testing
Study NCT01888497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine citrate
Description: 76 mg, oral, prior to bedtime on the night before performance testing
Study NCT02647632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01051076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VWF/FVIII concentrates
Description: 200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
Study NCT01888497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam
Description: 0.5 mg, oral, prior to bedtime on the night before performance testing
Study NCT01888497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, prior to bedtime on the night before performance testing
Study NCT01598116 — intervention group
Intervention type: PROCEDURE
Intervention: Urine collection and ultrasonography
Description: Bagged urine collection and ultrasound at each visit
Study NCT01598116 — intervention group
Intervention type: PROCEDURE
Intervention: Urine collection
Description: Bagged urine collection
Study NCT03240575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed Dose Combination
Study NCT03240575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: Fixed Dose Combination
Study NCT03240575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fixed Dose Combination
Study NCT03240575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Fixed Dose Combination
Study NCT00827411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel / Prasugrel
Description: modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
Study NCT00827411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VerifyNow
Description: point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Study NCT00827411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and clopidogrel / Prasugrel
Description: aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
Study NCT00827411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel / Prasugrel
Description: maintenance dose of clopidogrel / Prasugrel and aspirin
Study NCT00827411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Interruption of clopidogrel / Prasugrel after one year of follow-up
Study NCT02208791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
Study NCT02208791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT00228891 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Effect of Pulsatile IV insulin on diabetic neuropathy
Description: Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
Study NCT00228891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Pulsatile IV Insulin on diabetic neuropathy
Description: Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
Study NCT01368575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG
Study NCT01368575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined with MV repair with remodeling annuloplasty rigid ring
Description: CABG combined with MV repair with remodeling annuloplasty rigid ring
Study NCT03780452 — intervention group
Intervention type: DEVICE
Intervention: novel dynamic compression intramedullary nail
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
Study NCT01249625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 Respirator
Description: Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
Study NCT01249625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical/surgical mask
Description: Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
Study NCT05058027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 6g prefilled syringe
Study NCT05058027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe
Study NCT02249975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloon Focal Ablation System
Description: The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~* Device malfunctions~* Adverse events~* Patient Pain~* Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus.
Study NCT01200693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting stent
Description: Implantation of Sirolimus eluting stent
Study NCT01368575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
Description: CABG combined with MV repair with remodeling annuloplasty
Study NCT01200693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Implantation of Everolimus eluting stent
Study NCT01368575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG and MV replacement
Description: coronary artery bypass grafting and mitral valve replacement
Study NCT02595736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SC)
Description: Administered SC
Study NCT02595736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200327 (SC)
Description: Administered SC
Study NCT02595736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200327 (IV)
Description: Administered IV
Study NCT02595736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IV)
Description: Administered IV
Study NCT01081808 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EGFRBi-armed autologous activated T cells
Description: EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
Study NCT03938116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing Hearts Together
Description: Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
Study NCT01394575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with an simultaneous integrated boost
Description: IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
Study NCT02306980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
Study NCT01815281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Mechanical Stimulation (GONDOLA)
Study NCT01815281 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foot Mechanical Stimulation (GONDOLA)
Study NCT04535284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Health Coaching-in-Context that consists of up to 10 sessions, arranged once-a-week or multiple times a week based on convenience of scheduling for up to 10 weeks. The program targets improved caregiver health through occupational therapy coaching.
Study NCT01320683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02159547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg intravenous arveles in 50 ml saline in 5 minutes